RCT: Fuzuloparib maintenance therapy in patients with platinum-sensitive, recurrent ovarian carcinoma.
20 Apr, 2022 | 09:09h | UTCFuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)